Jpmorgan Chase & CO Evolus, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Evolus, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 727,891 shares of EOLS stock, worth $6.65 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
727,891
Previous 138,149 426.89%
Holding current value
$6.65 Million
Previous $1.53 Million 474.16%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
BUY
$9.47 - $15.04 $5.58 Million - $8.87 Million
589,742 Added 426.89%
727,891 $8.76 Million
Q4 2024

Feb 12, 2025
SELL
$10.84 - $17.45 $344,462 - $554,508
-31,777 Reduced 18.7%
138,149 $1.53 Million
Q3 2024

Dec 26, 2024
SELL
$10.66 - $17.48 $469,338 - $769,609
-44,028 Reduced 20.58%
169,926 $2.75 Million
Q3 2024

Nov 08, 2024
SELL
$10.66 - $17.48 $469,338 - $769,609
-44,028 Reduced 20.58%
169,926 $2.75 Million
Q2 2024

Dec 26, 2024
BUY
$10.45 - $13.76 $460,092 - $605,825
44,028 Added 25.91%
213,954 $2.32 Million
Q2 2024

Aug 12, 2024
SELL
$10.45 - $13.76 $352,185 - $463,739
-33,702 Reduced 13.61%
213,954 $2.32 Million
Q1 2024

Dec 26, 2024
BUY
$9.99 - $14.91 $776,522 - $1.16 Million
77,730 Added 45.74%
247,656 $3.47 Million
Q1 2024

May 10, 2024
BUY
$9.99 - $14.91 $2.09 Million - $3.12 Million
209,183 Added 543.71%
247,656 $3.47 Million
Q4 2023

Dec 26, 2024
SELL
$7.6 - $10.53 $999,042 - $1.38 Million
-131,453 Reduced 77.36%
38,473 $405,000
Q4 2023

Feb 12, 2024
SELL
$7.6 - $10.53 $702,445 - $973,256
-92,427 Reduced 70.61%
38,473 $405,000
Q3 2023

Nov 14, 2023
BUY
$7.15 - $10.2 $691,626 - $986,656
96,731 Added 283.1%
130,900 $1.2 Million
Q2 2023

Aug 11, 2023
BUY
$7.23 - $10.52 $31,602 - $45,982
4,371 Added 14.67%
34,169 $248,000
Q1 2023

May 18, 2023
BUY
$7.81 - $11.05 $211,869 - $299,764
27,128 Added 1016.03%
29,798 $252,000
Q1 2023

May 11, 2023
SELL
$7.81 - $11.05 $841,886 - $1.19 Million
-107,796 Reduced 97.58%
2,670 $22,000
Q4 2022

Feb 13, 2023
BUY
$6.52 - $8.95 $567,781 - $779,392
87,083 Added 372.42%
110,466 $829,000
Q3 2022

Nov 14, 2022
BUY
$7.76 - $13.72 $14,433 - $25,519
1,860 Added 8.64%
23,383 $188,000
Q2 2022

Aug 11, 2022
SELL
$10.22 - $13.94 $8,063 - $10,998
-789 Reduced 3.54%
21,523 $250,000
Q1 2022

May 11, 2022
BUY
$5.22 - $11.78 $27,138 - $61,244
5,199 Added 30.38%
22,312 $251,000
Q4 2021

Feb 10, 2022
BUY
$5.37 - $8.38 $26,307 - $41,053
4,899 Added 40.11%
17,113 $111,000
Q3 2021

Nov 12, 2021
BUY
$7.36 - $13.67 $89,895 - $166,965
12,214 New
12,214 $94,000

Others Institutions Holding EOLS

# of Institutions
187
Shares Held
51.9M
Call Options Held
142K
Put Options Held
58.4K
View Full List

About Evolus, Inc.

EOLS Quotes by TradingView
  • Ticker EOLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 56,094,800
  • Market Cap $513M
  • Description
  • Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...
More about EOLS
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email